ERBB2 and breast carcinoma: A phase 3 study with advanced hormone receptor-positive, HER2 negative breast cancer patients who relapsed or progressed during previous hormone therapy was performed to compare the efficacy of palbociclib and fulvestrant versus placebo and fulvestrant.